Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18828495 | 0.79 | HTR1A (0.50) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30285578 | 0.76 | HTR1A (0.55) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21590061 | 0.76 | HTR1A (0.55) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL28608577 | 0.76 | HTR2C (0.47) | MAPTTAS1R3TAS1R1TAS1R2IKBKB | |
| SCHEMBL21733883 | 0.75 | NISCH (0.37) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19524597 | 0.74 | MAPT (0.50) | MAPTALDH1A1 | |
| SCHEMBL17996703 | 0.73 | MTNR1A (0.53) | MAPTIKBKBIDO1ALDH1A1 | |
| SCHEMBL3241051 | 0.72 | TP53 (0.64) | HTR1AMAPTTAS1R3TAS1R1TAS1R2 | |
| Dimethylamine SCHEMBL6541566 | 0.71 | HTR1A (0.54) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| Dimethylamine SCHEMBL6542138 | 0.71 | HTR1A (0.50) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | HTR1A 4771/4885HTR7 4535/4885MAPT 3269/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | HTR1A 4771/4885HTR7 4535/4885MAPT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.